Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two midstage trials of obeldesivir.

Gilead Sciences and Kymera Therapeutics have entered into a partnership worth as much as $750m to develop a molecular glue degrader (MGD) programme with “broad oncology treatment potential”.

Gilead Sciences (NasdaqGS:GILD) recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue degrader program targeting CDK2, enhancing its oncology pipeline ...

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Gilead’s daily antiviral pills can prevent HIV transmission and slow AIDS. While an HIV vaccine remains the Holy Grail, Gilead’s new long-lasting injection, lenacapavir, is the next best thing.

The Indian government has long insisted that the social hierarchy has no place in the country, which banned caste discrimination in 1950.

(CNN) — For millions across India, a rigid caste system thousands of years old still dictates much of daily life – from social circles to dating pools to job opportunities and schooling.

A caste census will lead to demands for reservations in jobs and education proportional to the population share. Hindu upper castes are anxious that their share will shrink.

Now, Gilead Sciences has agreed to fork over $202 million to resolve allegations that it operated HIV speaker programs as a way to offer inducements for doctors to write prescriptions.